A Phase 2/3 Randomized Double-blind Placebo-controlled Multicenter Prospective Study to Assess the Efficacy Safety and Pharmacokinetics of Orally Administered Epetraborole in Patients with Treatment-refractory Mycobacterium avium Complex Lung Disease (MACrO2)

Brief description of study

Phase 2/3, double-blind, placebo-controlled study of epetraborole + OBR versus placebo + OBR in patients with treatment-refractory MAC lung disease. This study features a sequential Phase 2/3 approach with an initial Phase 2 assessment of symptom-based clinical responses, microbiological responses, safety, and PK associated with oral epetraborole, prior to the superiority analysis of oral epetraborole versus placebo in the Phase 3 part of the study. Results from the Phase 2 part of the study will inform of the specific PRO, the symptom-based clinical response definition, and the microbiological response criteria to be used in the Phase 3 part of the study. In addition, PK analyses from a Sentinel PK group in the Phase 2 part of the study will verify the dosage of oral epetraborole in patients with treatment-refractory MAC lung disease.


Clinical Study Identifier: s22-00181
ClinicalTrials.gov Identifier: NCT05327803
Principal Investigator: Doreen J Addrizzo-Harris.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.